Edition:
India

Sumitomo Dainippon Pharma Co Ltd (4506.T)

4506.T on Tokyo Stock Exchange

2,454JPY
20 Jul 2018
Change (% chg)

¥-25 (-1.01%)
Prev Close
¥2,479
Open
¥2,480
Day's High
¥2,513
Day's Low
¥2,445
Volume
1,119,200
Avg. Vol
1,342,832
52-wk High
¥2,536
52-wk Low
¥1,397

Chart for

About

Sumitomo Dainippon Pharma Co., Ltd., is a pharmaceutical company. The Japan segment manufactures and sells ethical and general use drugs. The North America segment manufactures, develops, purchases and sells ethical drugs. The China segment manufactures and sells ethical drugs through its consolidated subsidiary. The Other... (more)

Overall

Beta: 0.76
Market Cap(Mil.): ¥604,410.31
Shares Outstanding(Mil.): 397.90
Dividend: 11.00
Yield (%): 1.18

Financials

  4506.T Industry Sector
P/E (TTM): 17.23 30.93 32.76
EPS (TTM): 88.18 -- --
ROI: 6.47 15.07 14.61
ROE: 7.80 16.60 16.34

BRIEF-Sumitomo Dainippon Pharma and JCR Pharmaceuticals sign license agreement

* Says it and JCR Pharmaceuticals Co Ltd signed a license agreement on Blood-Brain Barrier Penetration Technology for creation of a therapeutic agent for Central Nervous System Diseases

26 Feb 2018

BRIEF-Sumitomo Dainippon Pharma says change of president

* Says it appoints Masayo Tada as chairman of the board, and Hiroshi Nomura as president, effective April 1

23 Feb 2018

BRIEF-Intercept Pharma Says Sumitomo Dainippon Pharma Enters Into Amendment To Certain License Agreement

* INTERCEPT PHARMA SAYS ON FEB 13, CO, SUMITOMO DAINIPPON PHARMA ENTERED INTO AMENDMENT TO CERTAIN LICENSE AGREEMENT DATED AS OF MARCH 29, 2011

17 Feb 2018

BRIEF-Sumitomo Dainippon Pharma files patent infringement lawsuits regarding lATUDA® in U.S.

* Says it filed patent infringement lawsuits jointly with its U.S. subsidiary, Sunovion Pharmaceuticals Inc. on February 13(U.S. Eastern Time) in the U.S. District Court for the District of New Jersey against Emcure Pharmaceuticals Ltd. and in the U.S. District Court for the District of Delaware against Amneal Pharmaceuticals LLC regarding their submissions of Abbreviated New Drug Applications for generic copies of LATUDA®(lurasidone HCl tablets)

14 Feb 2018

BRIEF-Sumitomo Dainippon Pharma unit says positive topline results from study of apomorphine sublingual film

* Says unit Sunovion Pharmaceuticals Inc. (Sunovion) announced topline results from its pivotal Phase 3, randomized, double-blind, placebo-controlled clinical trial, CTH-300, that evaluated apomorphine sublingual film (APL-130277) in patients with Parkinson’s disease (PD) who experience motor fluctuations (OFF episodes)

30 Jan 2018

Earnings vs. Estimates